ANNEXON, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
ANNEXON, INC. (ANNX) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $83.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-12
- ANNEXON, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $50.00M, a 62.06% decline year-over-year.
- ANNEXON, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $33.00M, a 79.31% decline year-over-year.
- ANNEXON, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $38.50M, a 77.75% decline year-over-year.
- ANNEXON, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $72.60M, a 27.25% decline year-over-year.
- ANNEXON, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $402.40M, a 10.20% increase from fiscal 2024.
- ANNEXON, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $365.15M, a 104.01% increase from fiscal 2023.
- ANNEXON, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $178.98M, a 0.46% increase from fiscal 2022.
- ANNEXON, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $178.17M, a 33.93% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $50.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $83.00M 10-Q · filed 2026-08-12 | $121.50M derived: sum of 3 quarters · filed 2026-08-12 | $194.10M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $33.00M 10-Q · filed 2026-05-07 | $71.50M derived: sum of 2 quarters · filed 2026-05-07 | $144.10M derived: sum of 3 quarters · filed 2026-05-07 | $275.90M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $38.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $111.10M derived: sum of 2 quarters · filed 2026-03-30 | $242.90M derived: sum of 3 quarters · filed 2026-08-12 | $402.40M 10-K · filed 2026-03-30 |
| 2025-09-30 | $72.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $204.40M derived: sum of 2 quarters · filed 2026-08-12 | $363.90M 10-Q · filed 2025-11-10 | $536.95M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $131.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $291.30M 10-Q · filed 2026-08-12 | $464.35M derived: sum of 3 quarters · filed 2026-08-12 | $564.15M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $159.50M 10-Q · filed 2026-05-07 | $332.55M derived: sum of 2 quarters · filed 2026-05-07 | $432.35M derived: sum of 3 quarters · filed 2026-05-07 | $501.65M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $173.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $272.85M derived: sum of 2 quarters · filed 2026-03-30 | $342.15M derived: sum of 3 quarters · filed 2026-03-30 | $365.15M 10-K · filed 2026-03-30 |
| 2024-09-30 | $99.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $169.10M derived: sum of 2 quarters · filed 2025-11-10 | $192.10M 10-Q · filed 2025-11-10 | $214.40M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $69.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $92.30M 10-Q · filed 2025-08-14 | $114.60M derived: sum of 3 quarters · filed 2025-08-14 | $176.19M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $23.00M 10-Q · filed 2025-05-12 | $45.30M derived: sum of 2 quarters · filed 2025-05-12 | $106.89M derived: sum of 3 quarters · filed 2025-05-12 | $150.90M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $22.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $83.89M derived: sum of 2 quarters · filed 2025-03-03 | $127.89M derived: sum of 3 quarters · filed 2025-03-03 | $178.98M 10-K · filed 2025-03-03 |
| 2023-09-30 | $61.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $105.59M derived: sum of 2 quarters · filed 2024-11-14 | $156.68M 10-Q · filed 2024-11-14 | $180.18M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $44.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $95.09M 10-Q · filed 2024-08-12 | $118.59M derived: sum of 3 quarters · filed 2024-08-12 | $151.59M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $51.09M 10-Q · filed 2024-05-13 | $74.59M derived: sum of 2 quarters · filed 2024-05-13 | $107.59M derived: sum of 3 quarters · filed 2024-05-13 | $149.85M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $23.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $56.50M derived: sum of 2 quarters · filed 2024-03-26 | $98.77M derived: sum of 3 quarters · filed 2024-03-26 | $178.17M 10-K · filed 2024-03-26 |
| 2022-09-30 | $33.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $75.27M derived: sum of 2 quarters · filed 2023-11-13 | $154.67M 10-Q · filed 2023-11-13 | $225.69M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $42.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $121.67M 10-Q · filed 2023-08-07 | $192.69M derived: sum of 3 quarters · filed 2023-08-07 | $221.69M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $79.40M 10-Q · filed 2023-05-08 | $150.43M derived: sum of 2 quarters · filed 2023-05-08 | $179.43M derived: sum of 3 quarters · filed 2023-05-08 | $207.43M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $71.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $100.03M derived: sum of 2 quarters · filed 2023-03-06 | $128.03M derived: sum of 3 quarters · filed 2023-03-06 | $133.03M 10-K · filed 2023-03-06 |
| 2021-09-30 | $29.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $57.00M derived: sum of 2 quarters · filed 2022-11-03 | $62.00M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $28.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $33.00M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $5.00M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |